Vaccines, 1.3 million doses AstraZeneca in Pratica di Mare

2021-04-02T08:57:15.394Z

Over 1.3 million doses of AstraZeneca (Vaxzevria) have arrived at the vaccination hub of the Defense of Pratica di Mare. This arrival concludes the vaccine deliveries planned for the first quarter of 2021. The doses, it is explained, will be promptly distributed throughout the country with carriers from the Italian Post Office (SDA) and Defense. Berlin vaccine commission draft: second dose not with AstraZeneca The German Standing Vaccination Commission (Stiko) advises people under 60 who received the first dose of AstraZeneca to have a different vaccine inoculated for the second dose. This is what we read in a "draft decision" presented late last night by the German vaccination authority. In particular, Stiko recommends that a vaccine with mRNA be used for the second dose. At present in Germany the only other vaccines available that use mRNA technology are Biontech-Pfizer and Moderna. "The animal test data shows that the immune response is the same after the (second) heterologous vaccination," Stiko president Thomas Mertens told Spiegel. "Now it is necessary to clarify with scientific data how valid the protection is for humans. I hope that we will soon have data available" he continued. On March 30, the standing commission had recommended a stop to vaccination with AstraZeneca under 60 years of age. AstraZeneca: 30 cases of thrombosis in GB, but "safe vaccine" A total of 30 reports have reached the UK authorities of blood clotting events, linked to the Oxford / AstraZeneca anti-Covid vaccine. This was announced by the Medicines and Healthcare products Regulatory Agency (Mhra). The Agency has reported that it has received reports of 25 cases of serious and very rare blood clots, in addition to the five already recorded in recent weeks. The MHRA also made it clear that they did not see any of the same reactions in patients who received the BioNTech / Pfizer vaccine; and that adverse events, out of the 18.1 million doses administered in the UK, are extremely rare, about one in 600,000. The authorities also stressed that the vaccine is safe and there is no need to suspend its use as has happened in some European countries. Johnson & Johnson: we respect commitment for 200 million doses in the EU in 2021 "We remain confident in our ability to meet the commitment to provide 200 million doses of our single-dose Covid-19 vaccine to the European Commission and member states in 2021, starting deliveries in the second half of April, as previously communicated ". This was announced by the pharmaceutical company Johnson & Johnson after the blocking of a batch of active ingredient that does not comply with quality standards at Emergent Biosolutions in the USA. "We continue to plan to deliver over one billion doses of our Covid-19 vaccine by the end of 2021," the company says. Johnson & Johnson: US batch not compliant with quality never filled in The quality control process "has identified a batch of active ingredient that does not comply with quality standards at Emergent biosolutions in the USA. This batch has never passed the filling and finishing phases. of our manufacturing process. This is an example of the rigorous quality control applied to each batch of active ingredient. " This was announced by Johnson & Johnson after the blocking of an anti-Covid vaccine batch at Emergent. The issue "was identified and addressed with Emergent and shared with the US FDA. Quality and safety continue to be our top priority."